Fierce Pharma2h
In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...
New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
Devdiscourse4h
Reuters Health News Summary
"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...
Investing Snacks10h
Merck’s Keytruda Injection Faces Patent Battle With Halozyme
Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...
Piper Sandler Keeps Their Hold Rating on Halozyme (HALO)
Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $53.00.
Investing Snacks10h
AbbVie Expands SKYRIZI Access in Canada for Colitis
AbbVie has expanded the availability of SKYRIZI in Canada for ulcerative colitis, strengthening its presence in the ...